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ABSTRACT 
 
Focusing on the issue of genetic diagnostic testing and drawing on a 
series of semi-structured interviews with genetists, epidemiologists 
and clinicians in Spain, this paper highlights the limits of an 
individualistic approach to biomedicine, embedded in a larger process 
of biomedicalization of the health care system and geneticization of 
the medical research. In contrast to the current approaches on 
biomedical regulation, generally based either on bioethical 
considerations or on technical expertise, the present work suggests the 
necessity of integrating the decision making process with new 
approaches studying the social and political consequences of the 
massive implementation of biomedical technologies. Through the 
restoration of the centrality of the political discourse, new and 
effective systems of governance may allow the fertile participation of 
all the actors involved in the production, promotion, regulation and 
consumption of the new biotechnological treatments whilst, at the 
same time,  reconcile high participation with decisional efficacy. 
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Towards a  social and political approach to the public governance of the new 
biomedical technologies  
 
Vincenzo Pavone 
 
 
 
 
PREFACE 
 
In 2002, while half in the way of my PhD studies, I had the chance to have a phone 
interview with one of the main officers of the UNESCO International Bioethical 
Committee, whose name, for privacy reasons, I will not mention here. The interview 
was related to my application for a stage at the IBC. The UNESCO Officer listened to 
me carefully, while I was trying to explain why my research would have greatly 
benefited from a stage at IBC. However, at some point, the officer asked me what my 
research background was. At first, given my multidisciplinary background, I did not 
know how to answer but then I replied: I am a social scientist. Suddenly, the officer put 
our conversation to an end saying: “I see, but.. you know.. here at IBC we work on 
bioethical standard setting, we may need natural scientists, jurists and even moral 
philosophers but surely not social scientists. You should try at the MOST (Management 
of Social Transformation) Unit.”  
 
 
 
 
INTRODUCTION 
 
 
Whilst there exists an ever-growing literature on the ethical and legal implications 
of medical biotechnologies, at present there are only few up-to-date studies on their 
political and social implications. However, the rapid development of the new 
biomedical technologies is forcing policy-makers to face new types of decisional 
challenges. The first challenge comes from technologies like reproductive cloning that 
are ethically questionable but, given their expected limited diffusion, are not likely to 
have a remarkable social impact (G. Saint-Paul, 2003). The second type of decisional 
challenges may derive from technologies, like genetic screening techniques, that meet 
ordinary ethical requirements but, due to their potential diffusion, may carry a very high 
social and political impact (Shakespeare 1998, Petersen 2006). This second type of 
decisional challenges is precisely what this paper focuses on.  
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In spite of the eminently social nature of many of the issues associated with 
these techniques, the debate has been so far largely framed either on techno-scientific 
or in ethical/legal terms. The first generally focus on technical issues, such as the 
delivery of professional guidelines to secure international high quality standards of 
biomedical drugs, whilst the second are usually confined to normative issues and 
individual rights discourses. Either way, the result has been often the marginalisation 
of the political discourse and the de-responsabilization of political actors (Bora 2005, 
Petersen 2006). Drawing ispiration from some pioneer studies on biomedicalisation 
(Clarke 2003) and geneticization (Petersen 2002, 2006), this study aims to contribute to 
this research field through a social and political analysis of the challenges that the 
diffusion of genetic screening practices increasingly poses to the current system of 
governance of biomedical innovation and healthcare policy.  
In the first section, the paper tries to explore the extent to which some of the trends 
associated with biomedicalisation (Clark 2003) may also be affecting the European 
research and development agenda and the national healthcare systems. As geneticization 
of medical research and health care policy was identified by Adele Clarke as one of the 
driving forces behind biomedicalisation, in the second section the paper focuses on the 
relatioship between the diffusion of some genetic testing practices and a) the increasing 
emphasis on the genetic aspects of health, disease and reproduction b) the emergence of 
new healthcare policies based on a mix of predictive medicine, risk assessment methods 
and patient choice principles. Increasingly anchored to a controversial ‘right to be 
healthy’, as opposed to the traditional right to have access to healthcare services, these 
new policies seems to be supporting i) a geneticization of the medical research agenda 
and ii) the diffusion of new forms of genetic discrimination, whose ultimate risk is the 
endorsement of so called ‘weak eugenics’ selection processes.  
In the light of these suggestions, the paper explores the current situation in Spain 
in the third section. After having presented the main characteristics of the Spanish 
health care system, the paper analyses the social and political issues associated with 
genetic testing, focusing on their current diffusion and drawing from semi-structured 
interviews with nine experts, who belong to different fields of expertise but ordinarily 
deal with genetics.  In sum, both the economic indicators and the interviews seems to 
confirm some of the hypotheses formulated in the literature review. More specifically, 
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Spain seems to be experiencing a geneticization of research agenda whilst the 
generalisation of pre-natal genetic testing is, in fact, endorsing the diffusion of selective 
reproduction and clinical abortion.  
Consequently, it seems clear that the large-scale implementation of genetic 
technologies do not raise merely technical or ethical issues, but also socio-political ones, 
which the current technoscientific and/or bioethical approaches seems to be cognitively 
and structurally unable to address. Although some novelties may come soon from very 
recent initiatives, such as the PHGEN (Public Health Genomics European Network) 
Spanish National Task Force, the paper comes to the conclusion that current systems of 
health care regulation and policy have been so far poorly participative and too limited in 
their scopes to address the social and political challenges posed by the actual and 
foreseen implications of the current genetic testing practices.  
Therefore, in the last section, I have been tentatively outlining some proposals to 
develop new forms of participatory governance, in which a) the knowledge basis may 
broadened as to include new insights from empirical studies on the social and political 
impact of a large-scale implementation of the new biomedical technologies, b) the main 
institutional political actors may actively and successfully respond to the above 
mentioned challenges, and 3) effective participation of all the actors involved in the 
production, promotion, regulation and consumption of the new biotechnological 
treatments may be reconciled with decisional efficacy.  
 
 
1. Biomedicalisation, healthcare and social change 
 
Although far from having reached commercialisation, many of the new biomedical 
technologies have already raised expectations about health care policies, medical 
progress and life expectancy; have attracted huge economic investments, mobilised 
political interests, raised political concerns and encouraged new forms of political 
participation. In Italy, for instance, the prospect of endorsing the research on embryonic 
stem cells has provoked the emergence of new political clusters, not always overlapping 
with the traditional political divide between centre-left and centre-right. In addition, the 
advances of biomedical technology have been recently associated to the emergence of a 
new system of technology innovation, based on new economic actors characterised by a 
hybrid connection between scientific and entrepreneurial profiles (Lewontin 2000).  
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Adele Clarke (2003) argued that the recent technoscientific innovations in 
biomedicine are encouraging a transition from medicalisation to biomedicalisation, which 
is shifting the emphasis from enhanced control over external nature to the harnessing and 
transformation of our internal nature. In this transition, molecular biology and genetics 
played a crucial role, producing a geneticization of the research and medical approach, 
which now assumes that is cheaper and more effective to genetically redesign the 
problematic bodies rather than to treat specific problems of that body.  
Moreover, with its emphasis on risk assessment and surveillance, biomedicalisation 
is transforming the concept of ‘health’ into “an individual responsibility to be fulfilled 
through improved access to knowledge, self surveillance, prevention, risk assessment and 
the consumption of self help biomedical goods and services” (Clarke et al. 2003: 162). 
Consequently, biomedicalisation is encouraging an extension of medical jurisdiction, in 
the sense that various aspects of human life previously outside medical jurisdictions 
come to be constructed as medical problems. Second, it is also engineering a process of 
commodification of health, in which the large investments made by the public sector are 
socialising the costs of innovation without socialising its profits. Third, it is encouraging 
a reduction of public investments in ‘ordinary’ academic research and didactic 
activities, which is forcing the academic system to rely more and more on the funds 
provided by the private foundations and corporations, re-orienting their research agenda 
to the issues and needs of the funding agencies.  
In the following, I will try to explore how some of the dynamics associated with 
the transition from medicalisation to biomedicalisation may be affecting the European 
social and economic context in which the new medical biotechnologies are going to be 
commercialised. This section is mainly based on a comparative analysis of the data 
provided by the EU Commission, the OECD Report on Biotechnologies, the OECD 
Health Data 2005, the OECD Report on Biotechnology and Healthy Ageing (2002) and 
the WHO World Health Report 2006. 
According to the EU Commission data, in 2005 biotechnology has become the 
most funded research sector of the European Union. More specifically, in the years 
2003-2005 the EU Commission has allocated 255 millions euro to the biotechnology 
sector, as opposed to the 232 millions to the research programme on the structuring of 
the EU Area and to the 227 million allocated to nanotechnology.  
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The OECD report on Biotechnologies provides us with some valuable information 
about the market potential of biotechnologies. The biotech sector in Europe is generally 
characterised by small to medium size firms and the countries with the largest number 
of firms are France and Germany. Some European countries, such as Iceland and 
Denmark, have actually chosen to make biotechnology one of their main fields of 
development and show very high biotechnology intensity scores. Concerning the public 
investments in the biotech sector, Spain scores very well, followed by Finland and 
Denmark. In contrast, looking at the data on the employment, the leaders in Europe are 
Germany and the United Kingdom. The overall biotechnology sales reveals a dominant 
position of the US, whilst in Europe, Germany, UK and Denmark hold leading positions. 
In the OECD countries, health dominates biotechnology applications, with more than 
fifty per cent of total applications in biotechnology, more than eighty per cent of total 
biotech R&D expenditure, and more than sixty per cent of total sales. At the EPO, 
biotech patents applications grew at 8.3 % every year between 1991 and 2002 and now 
constitute 5.3 per cent of all patent applications. Thanks to a remarkable boost of 
venture capitals between 1994 and 2000, the European Union now accounts for 34.5 per 
cent of all biotech patent applications.  
The combined analysis of the two reports seems to confirm that the biotechnology 
sector is becoming one of most important economic sector not only for research and 
development but also in terms of economic growth and commercial potential. 
Considering that the large majority of biotechnology resources and sales relate to the 
health sector, I have tried to figure out the most recent situation and trends of this sector 
by comparing the data made available by the WHO and OECD on health expenditure 
and on drug expenditure, both in the private and in the public sector.  
In the OECD countries, general health expenditure, both private and public, has 
significantly increased between 1999 and 2003. The same trend affected the public 
expenditure on health per capita. In the countries where the health system is essentially 
public, we would expect the public budget bearing the large majority of the burden. 
However, the public share of the general expenditure on health has not significantly 
increased. These data, therefore, seem to indicate that the increase in expenditure has 
affected proportionately more the private sector, because of a general increase of out-
of-pocket expenditure. As to the pre-paid plans, in the UK the expenses for pre-paid 
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plans as part of total private health expenditure have significantly increased but in the 
remaining countries they have only moderately increased. The general trend, however, 
confirm that both public and private expenditure, at least in absolute terms, have been 
significantly increasing since 2002.  
In spite of all the investments and expenditures, the OECD Report on 
Biotechnology and Healthy Ageing (2002) warns us on the real contribution of the new 
biomedical technologies towards health improvement. Whilst it is true the quality and the 
length of life has improved in the OECD countries, the report argues that such a 
improvement is due much more to environmental, hygienic, nutritional and educational 
improvements than to the advances of medical technologies. In contrast, the speed of 
production and diffusion of new medical technologies seems to be accountable for more 
than fifty per cent of the recent growth of healthcare expenditure. The production of new 
medical technologies is encouraged by the diffusion of the new academia-industry 
hybrids, the rapid growth of government funds and the incentive provided by the 
patenting system. The diffusion is then encouraged by various supply-side incentives 
currently at work in the private and in the public health care systems, which are 
committed to increase the intensity of their care. On top of that, the diffusion of the new 
medical technologies is further encouraged by the frequent misuse of their application.  
The report comes to the conclusion that the overall contribution of medical 
biotechnology to date has been significant in economic terms but very small in 
therapeutic and clinical terms. In spite of the limited clinical results, the mutual 
reinforcement between the enormous economic interests and the huge medical 
expectations around biomedicine have the potential to activate some of the 
biomedicalisation dynamics also in European countries. However, having different 
R&D and health care systems, the european countries may not necessarily experiencing 
similar outcomes. Across the European countries, the public budget pays on average 75 
per cent of total health expenditure. Consequently, the worst scenarios evoked by the 
prospect of biomedicalisation seem to be nowadays realistic only for the UK, where the 
health care system increasinly relies substantially on private actors and private health 
insurance. In contrast, where the health care system is public based, the expensive 
dynamics of biomedicalisation will mainly affect adversely other sectors of public 
services and provisions, such as education, transports, public infrastructures and pension 
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schemes. The state will be expected to select the biomedical treatments to be included 
under public provision, facing dramatic political and social issues, such as the 
generalisation of negative eugenics practices. The increasing costs will also force a 
rescheduling of welfare priorities, especially with regards to pensions and public 
healthcare provisions. In addition, the limited amount of public resources will increase 
the level of political tension among the various stakeholders lobbying to have their 
interests rewarded. 
 
2. The social and political implications of genetic screening practices 
 
Inspired by the studies on biomedicalisation, recent scholar attention has been 
focusing on the relationship between the diffusion of genetic screening practices and the 
phenomenon of geneticization. Geneticization can be defined as the overwhelming 
emphasis on the genetic aspects of health and disease, arguably affecting medical 
research and clinical practice, health policy as well as current social understanding of 
health, disease and reproduction (Lippman 1992, 1994; Hedgecoe 1998, 2001, 2002). 
Geneticization is a highly problematic phenomenon because it seems to reinforce social 
and political discrimination on the basis of genetic characteristics, whether visible or 
invisible (Phelan 2005).  
A recent study on the generalisation of a mass neo-natal screening for cystic fibrosis 
(CF) in France casts some light on the mutual constitutive relationship between 
biomedicalization and geneticization (Vailly 2006). On the basis of a series of semi-
structured interviews with government officials, Vailly shows how the implementation of 
CF genetic screening as a mass medical practice, initially proposed by a small group of 
paediatricians and bio-molecular researchers, began to be successful when both the 
pharmaceutical industry and some patient groups got involved. The combination of the 
efforts of these three actors succeeded in winning first state support and, finally, the 
generalisation of the practice in the French health care system. The potential 
generalisation of the technique also caused a remarkable change in the way the CF patient 
groups framed the disease and the relative action. Until 1999 the CF associations were 
generally negative about genetic screening and emphasised the importance of the public 
programmes of support for the patients. After the constitution of an alliance with some 
pharmaceutical industries and some biomedical researchers in 1999, the CF associations 
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changed opinion and presented CF as a public health problem requiring mass public 
action. The new social block persuaded the policy-makers to increase public funds on this 
specific research and to adopt the screening test into the ordinary health care system. In 
turn, the genetic screening has produced a serious shift in both medical and scientific 
practice: first it concentrated its efforts more in the ‘prevention’ of CF than in the 
treatment of its symptoms and, second, it has also profoundly changed the concept of 
‘prevention’. The latter, in fact, no longer refers to the conditions encouraging the 
development of the disease (primary prevention) but to the actual reduction of the 
incidence of the disease in a given population (secundary prevention).  
A similar research has been conducted by Carine Vassy on the Down syndrome 
(2006). Vassy emphasises how biomedical researchers progressively turned into moral 
entrepreneurs and promoted the diffusion of generalised pre-natal genetic screening for 
Down syndrome. After carrying out some pioneer tests at the end of the Seventies,  these 
researchers began constituting a small network of patients groups, professionals and 
pharmaceutical industries. At the end of the Eighties, the network launched a massive 
media campaign and successfully lobbied on public authorities. Consequently, in spite of 
various technical and medical controversies, the public authorities decided to incorporate 
the screening technique as a routine practice into the public health care system. The 
progressive generalisation of the practice gradually promoted general consensus on 
medical abortions and the socialisation of costs of the screening practices, on the ground 
that it is cheaper to generalise the screening than to provide assistance to the individuals 
affected by the Down syndrome (Wald et al. 1992).  
From a social point of view, the campaign for the generalisation of the DS screening 
techniques has been usually presented as being conducted “in the name of women” and 
justified in terms of a supposedly vast social demand. The paper, however, shows clearly 
that the social demand is the result of the generalisation of the screening practice rather 
than the cause, and that women’s associations as such remained for a long time 
uninterested and got involved into the debate only very late. From an ethical point of view, 
the legitimacy of the screening practice has been framed and justified in terms of the 
individual right of self-determination and choice, usually associated with the norm of 
informed consent. Yet, the knowledge of the condition of the foetus produces the 
obligation to make a choice, which, in turn, makes parents responsible not only for the 
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birth of the child but, in a sense, also for the fact that the child carries the disease. 
Although parents remain free to decide whether to carry on pregnancy or not, the choice 
make them indirectly accountable. In other words, parents who now opt for carrying on 
the pregnancy may be considered socially accountable for the socio-economic burden 
associated with carrying the disease and for all the possible problems the child may 
experience in his/her life.  
In fact, the DS screening is a clear example of how a medical problem with a strong 
social cause – the increasingly late age in which women give birth for the first time – has 
been framed entirely as a genetic problem and ‘solved’ through mass genetic screening 
and medical abortion. The patient associations refuse to consider these practices as 
eugenics on the grounds of individual autonomy and informed choice (EAGS, Final 
Report of the workshop on Genetic testing: challenges for society, 2001: 10). Yet, the 
informed choice argument does not exclude these practices from eugenics, which includes 
negative eugenics, i.e the reduction of genetically defective people in the population 
(Huxley 1964). 1  Although under current bioethical approaches these practices may 
considered ethically acceptable, they constitute a challenge promoting social and political 
change in the general understanding of health, disease and reproduction, whose ultimate 
risk is the endorsement of selective reproduction and genetic discrimination, either 
involving the state or simply left to the market forces.  
A boundary work on in vitro fertilisation and pre-implantation genetic screening 
may actually casts some light on this issue (Ehrich et al. 2006). According to this study, 
the UK concept of welfare is experiencing a radical shift from a social welfare to a 
biomedical, genetic welfare. The overwhelming emphasis of the IVF/PGD staff 
interviewed on the genetic aspects of human health and well-being reveals the existence 
of a tension between a former social view of welfare, which sought to reconstitute the 
environment in order to accommodate the special needs of given social groups, and a new 
biomedical welfare that seeks to biologically refashion the problem by selecting the 
prospect individuals according to the biological standards currently upheld by the society. 
The crucial point is that our societies will be soon forced to decide whether they want to 
achieve justice and equity through social actions and policies or through the breeding 
                                                 
1 T. Shakespeare defines these practices as ‘weak eugenics’ (1998), whilst, according to the Routledge 
Encyclopedia of Philosophy (1998), all the practices aiming at the improvement of the human genetic pool 
should be considered eugenics. 
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selection of genetically resistant individuals, given that the two options – considering the 
current budget restraints on welfare provisions – may be at odd with each other. In the 
biomedical view of public welfare the solutions to reproductive problems are sought 
through an intervention at the individual genetic level that leaves the social context 
unaltered. On the one hand, there is a risk that the achievements in terms of social justice 
and social support for people carrying disabilities may be reconsidered and, in the long 
run, neglected. On the other hand, there is evidence to suggest that, under the biomedical, 
individualistic welfare model, the western society may experience a radical redefinition of 
citizens rights and responsibilities.  
For instance, Petersen (2002, 2006) has shown how under the new patient choice 
health care model, citizens in the UK are expected to take greater responsibilities for 
managing their own health risk. In turn, citizens have been asked to improve their general 
medical awareness and information, which, again, has encouraged citizens to ask for more 
tests, more visits, more or anticipated treatment. In this respect, the diffusion of genetic 
screening seems to speed up the process of biomedicalisation detected by Adele Clarke by 
medicalising healthy individuals into pre-patients who live under the social and 
psychological pressure of either ‘taking care’ of their life habits or entering early 
treatment, whenever possible. “There is potential for people, who have been genetically 
clustered into risk categories and do not take up preventive action, to be seen as failing in 
their duties of citizenship” (Petersen and Bunton 2002: 1223). The public governance of 
population’s health is, thus, achieved through the active participation of citizens now 
constituted as‘pre-patients’, because of the genetic risk they carry, and potential 
consumers, for all the drugs and treatments they may have access to (Castiel et al. 2006).  
Although basically confirming these trends, other empirical researches do not 
uphold such pessimistic views. A qualitative empirical research on the impact of adult 
pre-symptomatic genetic testing conducted in 2006 by Paula Sakko and other 
collaborators, for instance, does not seem to uphold the radical view expressed by 
Petersen and Bunton in 2002. Sakko’s findings, based on a series of semistructured 
interviews, show that, regardless of their educational level, the people did not really 
change their lifestyle after they had underwent thrombophilia genetic testing. Yet, their 
study confirms the mutually reinforcing relationship between genetic screening and 
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biomedicalisation: the people interviewed affirmed that they would rather prefer to begin 
medical treatment than to change their life-style.  
A recent study on the introduction of predictive medicine in life insurance shows 
that lifestyle information have a comparatively stronger impact on insurance behaviours 
than genetic information. However, it is true that risk assessment techniques, genetic and 
non-genetic, has encouraged a shift in the concept of health which is no longer defined as 
absence of disease but as absence of an increased risk of developing a disease. In addition, 
the insurers do consider risk factors already as if they were diseases, transforming 
epidemiological risks into pre-existing disorders (Van Hoyweghen at al. 2006: 1229). The 
introduction of predictive medicine has actually produced a rise of insurance premiums, 
notwithstanding the fact that the general health conditions have, on average, improved 
over the same period. With health increasingly being associated with ‘virtuousness’, the 
disease begins to be framed again as a ‘punishment’ for a reproachable behaviour, almost 
as a right reward for a bad moral conduct. Under these assumptions, if genetic risk 
assessment comes to be explicitly associated with an unhealthy lifestyle, the outcome may 
be the rise of a discriminated, un-insurable cast of people.  
If the insurance logic begins to be applied to public health care, the very concept of 
citizenship may be radically transformed. If the public health care begins sanctioning on the 
basis of life-style conduct and/or high risk genetic profiles, being a citizen will no longer be 
sufficient to get access to health care support: one will need to demonstrate that he/she is 
either a ‘good’ citizen or a ‘low-risk’ one. Either way, the basic concept of citizenship and 
citizen’s rights will be dramatically transformed. The proposal made recently by Tony Blair 
to modify the British health care system as to adopt the first criterion seems to be the most 
recent step into the direction above mentioned. Apart from the issue of discrimination, 
Blair’s proposal is based on very controversial neoliberal assumptions about individual 
responsibility and health care expenditure. In fact, the rise of health expenditure is not due 
to the worsening of general health conditions, which have actually improved, but to the 
enormous uptake of medical technologies and drugs (OECD Report 2002). In addition, 
the patients who might be discriminated because they are smokers, for instance, have 
already paid their contributions to the health care system twice, that is through both the 
income tax and the indirect taxes on tobacco. Third, this system holds a pure 
individualistic approach, which entirely neglects the social factors – i.e. education, 
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income, family conditions – associated with disease prevalence and life habits in the 
population. Finally, how can the state legally approve of tobacco consumption and then 
penalize tobacco consumers? 
The proposal advanced by Blair has to be considered within the broader debate on a 
on the principle of patient choice in health care that is taking place in the UK after the 
approval of the health care reform of 2005. On the one hand, the patient choice model 
attributes much more responsibility to health management to the citizens, upon whom the 
ultimate responsibility of preserving healthy conditions is placed. On the other hand, it 
claims to ‘empower’ citizens by involving them at all times from diagnosis to the final 
treatment and by providing them with a large amount of information and a variety of 
choices in terms of doctors, places and treatments. The most controversial aspect is that 
for the patient choice model to work, it necessary to redefine the identity of the patient. 
Whilst in the traditional understanding patients were not meant to choose, in the new 
system, extending the logic of the market to the health care system, the identity of the 
patient has to be constructed into a consumer.  
The basic idea behind this transformation is that the patient-consumer, is the best 
judge of the value of the health care process and outcomes. Once framed as a consumer, 
the patient is entitled with the right/duty to choose among alternatives in an open market, 
which now advocates the retreat of public health care provision to give space to private 
actors, arguably capable of providing a largest variety of options (Propper et al. 2006) A 
broader variety of options and a free market, however, would be useless if the patient-
consumers do not possess sufficient information to make choices. The increased diffusion 
of genetic screening seems to enter the process at this point by providing predictive 
information, which, through risk assessment profiles, helps to transform citizens in 
patients and patients into consumers. In turn, the process of empowerment makes the 
patient more responsible but also more accountable for the choices he/she makes not only 
in relation to the medical treatments he/she opts for but also for the lifestyle he/she adopts. 
This is the final twist of the patient choice revolution that has ultimately led Blair to 
propose sanction for people who conduct an unhealthy lifestyle.  
In relation to genetics and reproduction, a recent empirical study on the actual 
impact and feasibility of the patient choice approach seems to radically challenge the 
intellectual viability of the principles of choice in health care. The study, conducted by 
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Skully, Banks and Shakespeare (2006), focuses on the issue of choice related to pre-natal 
sex selection and comes to the conclusion that very often parents do not uphold neither a 
technical nor a utilitarian concept of choice. Rather, they formulate their choices on the 
basis of ethical and existential values, according to which sex selection is not desirable as 
it “is an expression of parental preference instead of a response to the future child’s 
needs” (Skully et al. 2006: 21). The prospective parents interviewed, in fact, seemed to 
believe that ideal parents must be prepared to give up some of their parental control even 
when such control is technically possible. This argument runs explicitly against the main 
assumptions of current secular bioethics views, which consider pre-natal selection as 
increasing reproductive choice, contributing to individual happiness and enhancing 
autonomy. The parents interviewed, in contrast, proposed the alternative concept of 
‘relational autonomy’, according to which good parents should pose a moral limit to their 
self-determination in order to preserve the child’s right to his/her autonomy. Within this 
framework, autonomy is not an “intrisic property held or expressed by an individual but a 
feature of a moral agent that comes into existence and is maintained through the agent’s 
interdependencies with, and responsibilities towards, the others (Skully et al. 2006: 30). 
Basically, the legitimate degree of choice with which parents may be endowed should be 
measured not against the abstract atomized background of a purely unconstrained 
individual but in relation to the degree of autonomy of the prospect child, because the 
parents’ autonomy only exists and makes sense within their relationship with the child.  
With its emphasis on the genetic aspects of these issues, the combination between 
biomedicalisation and genetisation – although possibly not as radically as often argued – 
seems to be encouraging new forms of genetic reductionism, emphasising human 
biological characteristics at the expenses of social and cultural ones, but also neglecting 
the mutually adaptive relationship between the human beings and the environment 
(Castiel et al. 2006). In addition, there is evidence to suggest that the former combination, 
through the diffusion of genetic screening practices, has also established a mutually 
constitutive relationship with the patient choice narrative about individual health 
management and the transformation of the health care system.  
Consequently, the social and political implications of the interaction among 
biomedicalization, geneticization and patient choice health care model may now be 
summarised as follow. First, they are encouraging the transformation of citizens into 
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patients-consumers and of the health care system from a public service to a private market, 
through a gradual retreat of public health care institutions and a parallel proliferation of 
private actors. Second, they are provoking an increasing demand of medical information 
and medical care. Third, they are orienting the research agenda towards a greater 
emphasis on the genetic roots of common diseases at the expenses of the studies on 
environmental and social factors. Fourth, they are stimulating the redefinition of the 
traditional concepts of health, reproduction and identity, with a greater emphasis on the 
genetic aspects of these concepts. Finally, they are engendering the formulation of new 
concepts of citizenship and political participation, in which genetic risk and virtuous 
behaviour become not only essential but also potentially discriminating factors.  
 
3. Genetic testing, health expenditure and healthcare changes in Spain 
 
Although only recently entered among the European Countries that have invested 
substantial resources on biotechnologies, Spain has managed to achieve significant results 
in the field by devoting increasingly larger resources to biotechnology R & D. Overall, in 
2004 Spain had 284 firms active in the biotechnology firms, which accounted for about 5 
per cent of the total firms active in R&D. The latter is an excellent result, especially if we 
consider the overall score of other European countries of similar or even bigger size. In 
general, Spain has been investing more in both medical and agricultural biotechnologies. 
In fact, Spain has one of the largest cultivations of BT maize in Europe, a result positively 
correlated to a low degree of politicization (PABE Report 2001) and to a relatively high 
level of trust that Spanish citizens show towards science and technology in general and 
biotechnology in particular (Lujan and Todt 2007).  
However, more than half of the total investments, employment and companies in 
Spain are concentrated in the health sector. From an economic point of view, health 
biotechnology applications account on average for 66% of total sales in the 
biotechnology sector. Between 1991 and 2002, the percentage of biotechnology 
applications as a percentage of the national total of EPO doubled, rising from 2.6 to 
nearly 5 per cent, placing Spain more or less in the middle of the classification, 
following Sweden but preceding the Netherlands. The Spanish biotechnology sector is 
largely dependent on public actors, initiatives and funds: the public share of total 
biotechnology R&D amounts to 69.5 per cent, which is actually the second largest share 
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among the OECD countries, after Norway. The public actors involved in biotechnology 
also account for 69 per cent whilst private business enterprises only accounts for 33 per 
cent of the total. If we consider that 95 per cent of these companies have received at 
least some sort of public funds or contributions, the relative weight of the public sector 
comes dramatically to the fore (OECD Report on Biotechnology 2006).  
According the WHO report on heath expenditure, Spain has also been affected by 
a relatively high increase of health expenditures. Health expenditure per capita has 
increased remarkably between 2000 and 2003, going from 1038 to 1541 dollars per year, 
the public share of which rose from 816 to 1098. Whilst the overall health expenditure 
as part of the GDP has remained more or less stable around 7.5 per cent, the overall 
expenditure has increased on average by 2.6 per cent every year between 1998 and 2003. 
The increase in the private portion of health expenditure, thus, seems to be due to 
private pre-paid plans, which are now purchased by 1/6 of Spanish population, rather 
that to out-of-pocket expenses.  
Although the Spanish health care system has been recently re-arranged in a 
strongly regionalised system, through a process of radical devolution, the most recent 
literature on the topic comes to the conclusion that this process has not produced 
substantial discrimination in access and care among the various autonomous 
communities (Lopez Casasnovas et al. 2005). Yet, depending on the system working, 
some regions, like Madrid, rely heavily on public institutions, whilst other regions 
(Catalonia, for instance) have opted for public reimbursement to private institutions. 
The public health care system is financed through a slightly progressive system national 
taxation; the revenues are later transferred to the Autonomous Communities, which 
spend on health between 60 and 70 per cent of their total budget. Overall, the state 
covers about 75 per cent of total health expenditure, whilst private expenditure accounts 
for the remaining 25 per cent. According to the most recent data, the increase in health 
expenditure in Spain confirms the suggestions made by the OECD report on Health 
Ageing on the impact of the large uptake of new technology and the relative abuse. In 
Spain, actually, ageing seems to be responsible only for nearly 8 per cent of the total 
health expenditure growth in 2001, whilst utilisation has been responsible for more than 
33 per cent (Lopez Casasnovas et al. 2005: 225). 
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According to the IPTS report on Genetic testing in Spain, published in 2004, 
genetic testing has experienced a remarkable diffusion in the last decade. The large 
majority of genetic tests are offered and implemented by public institutions, typically 
hospitals, universities and research centres. Private institutions account for 20 per cent 
of the total number of institutions performing genetic testing. Yet, 95 per cent of all the 
genetic testing performed in 2001 was run on public funds. Whilst quality assurance 
schemes were adopted only by seven centres, informed consent was required in more 
than 90 per cent of the tests performed. In 2001, there were in Europe 41 genetic tests 
commercially available, 19 of which were commercially available in Spain. One of the 
most interesting findings of the IPTS report was that the frequency of the test performed 
was not correlated to the actual clinical value of the tests but to the dominant research 
trends, as demonstrated by the large number of Alzheimer tests realised, in spite of their 
little clinical usefulness.  
Considering that one of the hypotheses derived from the literature review was that 
the diffusion of genetic screening techniques would encourage the large scale 
implementation of ‘weak eugenics’ measures, I will now focus for a moment on the 
impact of Down syndrome pre-natal screening in Spain. The Down syndrome is a 
genetic disorder that is associated with the presence of an extra copy of chromosome 21, 
and is therefore often called Trisomy. Although the causes of the mutation are unknown, 
the risk of having a baby carrying the genetic mutation increases with the age of the 
pregnant mother. The risk, however, increases slowly between 25 and 30 years old, 
significantly between 30 and 35, and dramatically after 35 years old  (Morris et al. 
2003). Apart from distinctive physical traits, the disease carries a series of alterations 
and dysfunctions, including a delay in mental development. Nonetheless, the average 
life expectancy of a person affected by the Down syndrome, which has significant 
increased in the last decades, now approaches fifty years (Noble 1998). There are 
various diagnostic instruments to detect the disease, some very intrusive and risky but 
reliable, such as amniocentesis, and others less reliable but also less intrusive. Being the 
most sensitive and reliable, the genetic test is becoming the privileged practice in health 
care systems, as the French experience demonstrates.  
In Spain, some studies have been carried out by hospitals and medical research 
institutions to study the prevalence of the disease (Martinez Frías et al. 2000; E. 
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Bermejo et al. 2006). These studies compare the data on Down syndrome births before 
and after the legalisation of abortion, occurred in 1985. Until then, the prevalence had 
remained stable around 14 children affected every 10.000 life births. In 1985, the 
average age of Spanish mothers at first pregnancy was about 25 years. If all of the 
women at first pregnancy in Spain were 25 years old, the expected amount of down life 
births, according to the most updated specialized literature, would be around 7 every 
10.000. Obviously the real prevalence is higher, because the number of women aged 
between 30 and 35, which has a significant higher risk, contributes proportionally to 
produce higher final outcomes. In any event, starting with 1985, the actual prevalence of 
Down syndrome life births has decreased, initially slowly and then dramatically to the 
point that the current prevalence is indeed around 7 every 10.000 (2005). According to 
current average age of Spanish women at their first pregnancy, which is now around 
29.33 years, the theoretical expected prevalence should be around 9.91, whilst the 
natural prevalence, considering the larger portion of pregnant women between 30 and 
35, should be higher than the one registered in 1985. In 1996, for instance, the natural 
birth prevalence in the UK was estimated around 16.7 per 10.000 (Mutton et al. 1998). 
It is clear that the dramatic reduction is due to therapeutic abortion, which has increased 
remarkably since 1995.  
In a study carried out in Santander in 1998, the natural prevalence has been 
actually reconstructed combining the data on Down syndrome life births (7), and the 
numbers of abortions carried out as a result of Down syndrome pre-natal diagnosis (17): 
the final result (24), which however includes potential spontaneous abortions, was much 
higher than the natural prevalence in 1985 (Martinez Frias et al. 2000: 406). If we look 
at the specific subgroups of women between 33 and 35 years, which today in Spain 
accounts for more than one third of all pregnant women, the impact of therapeutic 
abortion is dramatic: although the natural prevalence should be around 73 affected 
births out of 10000, the actual prevalence in 1998 was zero.  
The remarkable reduction of the prevalence of Down syndrome within the 
population has been hailed as a great success in the prevention of the diseases. Without 
entering the moral dimension of the issue, I would simply underline that technically 
speaking the disease as such as not been prevented – given that the expected prevalence 
of the disease has actually been increasing along with the age of first pregnancy – but 
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the birth of individuals carrying the specific genetic mutation. This actually confirms 
the hypothesis associating the diffusion of genetic screening with a radical shift from 
primary prevention to secundary prevention as well as the hypothesis suggesting a shift 
from a social conception to a genetic conception of public welfare.  
This shift is further illustrated by the recent Assisted Reproduction Law, approved 
in 2006 by the Spanish Parliament (Romeo Malanda 2006). The law is one of the most 
liberal act existing so far in Europe. Although it does not allow cloning for research 
purposes, it incorporates the new concept of pre-embryo; permits research on 
supernumerary embryos, whose production is no longer restricted; and encourages ova 
donation. In addition, it allows both pre-implantation and pre-natal screening. More 
specifically, pre-implantation screening is framed as a possible remedy to couples with 
hereditable genetic diseases, which now may use pre-implantation screening not only to 
avoid the implantation of an embryo carrying ‘serious genetic diseases’ but also to 
detect ‘other alterations’ that may negatively affect the ‘viability’ of the pre-embryo and 
even to select the embryo that looks more compatible with a third person (typically for 
transplantation reasons). The ultimate aim, as specified in the Act, is to carry on a 
pregnancy with ‘genetically healthy embryos’.  
Although implicitly referring to the hereditable genetic diseases of the parents, 
future extension of the ‘genetically healthy’ definition may become in the near future 
one of the most controversial concepts ever to influence our current understanding of 
health, identity and reproduction. The point is that, beside very few monogenetic 
disorders caused by the alterations of genes with a high penetrance, being ‘genetically 
healthy’ does not make sense. First, it as been estimated that each of us carries around 
200 faulty genes, although often they are recessive in the pair (Morrison 2005), and 
second, the ‘unhealthy’ characteristics of the genotype have always to be assessed in 
relation to the biological and social environment, which is not static and change over 
time, largely as a result of our own actions (Vineis et al. 2001, Porta 2003, Hunter 2005, 
Luch 2005, Porta 2005). 
The gradual emergence of new concepts like genetically healthy or genetically 
compatible seems to confirm the trend towards a more genetic and individualistic 
approach affecting not only the directions and priorities undertaken by the biomedical 
and the clinical research systems but also the new healthcare policies and the juridical 
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framework that underpins them. A recent issue of the Spanish periodical Expansion 
(21th March 2005) provides a further example of how the overwhelming emphasis on 
the genetic aspects of health, identity and reproduction is affecting the social context in 
Spain. According to the periodical, twenty big companies in Spain have recently offered 
a predictive genetic screening scheme to their top managers. When interviewed, the 
human resource directors have justified the initiative as a way to provide new and 
crucial information to their managers to help them planning their personal and family 
life well ahead of time. In the article, the predictive reliability of the tests is assessed at 
95 per cent, a figure that highly overestimates the real predictive power of any genetic 
pre-symptomatic test. While the test is also available to partners and children, the results 
are disclosed directly to the managers, who, depending on the disease for which a risk is 
detected, may then ask for medical consultancy internal or external to the company. 
According to the data of the biotech company in charge of this service, only one out of 
four managers has so far refused to take the test. The most intriguing issue, however, is 
that the large majority of these firms have asked to remain anonymous because they 
were afraid that the trade unions, if informed, would seek to extend this service to all 
workers. 
 
3.1 Genetics, healthcare and participation in Spain: the interviews 
 
To explore the phenomenon more in depth, a series of semistructured interviews 
has been conducted with experts in genetic medicine across various regions in Spain. 
The group of experts interviewed includes one bioethicist, one expert in 
pharmacogenetics, two epidemiologists, an expert in health technology assessment, as 
well as three medical genetists (two clinicians and one researcher). The main goal of 
these interviews was to explore the extent and the implications of the increasing 
diffusion of genetic testings as they were understood by the various types of experts 
who actually deal with genetic testing technology. The questionnaire, structured around 
ten open questions, focused on five main issues: a) the contribution of genetics in 
medical research and clinical practice b) the nature of genetic information c) the current 
diffusion of genetic screening techniques and d) the idea of participatory governance, 
with a specific reference to the role of patient groups. The complete list of questions is 
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available in the annex at the end of the paper. The experts were selected by using the 
snowball technique, identifying first one expert for each subgroup and then asking them 
to suggest further colleagues to interview. At the time of writing, nine out of fifteen 
experts have accepted to collaborate. The interviews have been recorded, transcribed, 
and analysed by the same researcher.  
Although the experts agreed that the contribution of genetics in medical research 
has been so far significant, almost all of them admit that the contribution of genetic 
medicine in the clinical practice so far has been marginal and largely overestimated. In 
case only, one genetist suggested that the relatively negligible contribution to medical 
practice is not due to intrisic limits of genetic research, but to the poor knowledge and to 
the prejudices of the majority of the colleagues who do not know enough of genetics. 
Those, who are more optimistic, identify pharmaco-genetics as the very field in which 
genetics is more likely to positively contribute to clinical practice.  
Both supporters and sceptics agree that both the private and the public research 
agenda have been increasingly focusing on genetic aspects of human health, diseases 
and reproduction, switching also resources from basic to applied research Although this 
new emphasis has been increasingly securing research funds to genetic research, the 
genetists suggest that, compared to the huge potentials, this is far from being 
satisfactory. In contrast, the epidemiologists complain that this has 1) sensibly reduced 
public funding of epidemiological studies on complex diseases, in which the genetic 
profile of individuals play a limited role and 2) provoked an excessive emphasis on the 
genetic components of complex diseases, whilst inducing medical research to neglect 
the variety social and environmental factors, playing a crucial role in the development 
of a number of diseases. In fact, Genetist 1 affirmed “I am a member of the evaluating 
committee on research proposal in biomedicine, and I can tell you: a research proposal 
that does not include substantial research into the genetic aspects of common diseases 
has not a single change to get public funding” (Genetist 1; questions 1-2).  
Among the environmental and social factors arguably neglected by current trends 
in medical research, the experts have stressed the huge impact of life habits, like eating, 
smoking and drinking, and polluting agents present in the environment (such as lead, 
DDT and dioxine) for which there is evidence of much more dramatic impact vis-à-vis 
the development of common diseases like cardiovascular disorders and diabetes. The 
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totality of experts, though, agree that the genetic profile of each individual does 
predispose differently to the development of such diseases.  
Although placing different emphasis on how much the genetic profile predisposes 
to certain diseases, the experts seemed to share the opinion that the perspective often 
upheld by the media and the public authorities dealing with the national R&D plans, 
which considers the genes responsible for the development of main common diseases is 
both scientifically flawed and ideologically characterised. Scientifically flawed because 
recent development in genetic research do show that the genome does not function in a 
deterministic way, but is largely flexible and works along a complex system of 
interactions among genes and between the genome and the environment.  
“The genome is a complex system, it does not function in a deterministic 
way. Therefore, it does not really predict, it only gives us information about 
susceptibility and predispositions, which may, or may not, facilitate the 
development of a given disease, depending on various non-genetic and 
environmental factors. In a word, the gene does not cause, it only 
predisposes. (Genetist specialised in congenital anomalies).  
 
The genetic-based perspective is also ideologically characterised because it 
overemphasises the role of individual genetic predispositions in order to overshadow 
the social and the environmental factors, and to avoid social and political responsibility 
for the lack of research interest and political intervention: 
“The genetic variation among the human population is very small, but the 
differences in health conditions across the globe are huge, even within the 
western world. The genetic variation, at least at the population level, cannot 
explain neither such health differences nor their historical trends”. 
(Epidemiologist 2)  
 
“There is a constant exageration of the genetic causes in common, complex 
diseases. As a result, crucial medical information about the impact of 
environmental and social factors, like DDT or lead contamination, is not 
being taken into account. In fact, we could even speak of a genetic 
extremism, which is litreally fundamentalist, given that it pretends to deal 
with the foundations of the human biological nature. The governments try to 
make people overlook completely their political responsibility towards the 
social causes of common diseases, and often biotechnology and molecular 
biology, with false hopes and genetic reductionism, actually endorse such a 
trend” (Expert in clinical and molecular epidemiology)   
 
In fact, a number of experts did not deny the possibility that the genetics may 
yield excellent clinical results but suggested that to achieve these results should focus 
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more on the actual interaction between the individual genome, the genetic alterations 
occurred during life-time and the environmental factors, rather than on simple causal 
connections between the genome and the future development of complex diseases. 
The relationship between the environment and the genome is very important. 
Here in Spain we have, for instance, the project INMA (infancia e 
medioambiente) that studies, among other things, the interaction between 
environmental polluting agents and genetic variation in children from before 
birth to teen-age. (Expert in preventive medicine and public health) 
 
Modern biology is gradually reaffirming the crucial role of the 
environmental factors in the regulation of genetic expression. In fact, to 
understand better the interaction between the genome and the environment 
we need to integrate epigenetic and classical genetic mechanisms” (Expert 
in clinical and molecular epidemiology). 
 
It is really important, in the next ten years, how we are going to understand 
the interaction between the genome and the environment. A better 
understanding of this interaction may in fact yield important results. (Expert 
in genetic medicine) 
 
In contrast to common understandings of genetic information as requiring special 
legal protection because of its uniquely predictive nature, all the experts affirmed that 
genetic information is not qualitatively different from ordinary medical information. In 
fact, they suggest that personal non-genetic medical information is much more reliable 
in predicting future diseases:  
“I don’t see how the genetic information could make a patient more 
vulnerable than his ordinary clinical history, which, in fact, provides much 
more information than his/her genetic material, although in case we are 
talking about specific monogenic diseases the genetic information is much 
more relevant.” (Expert in pharmaco-genetics 1).  
 
However, they suggest treating genetic information confidentially not so much 
because it is highly predictive but because it is permanent and partially shared with 
relatives. In general, they suggest that access to genetic information should always be 
granted to scientists and researchers in order to ensure further medical advances, but 
highly restricted vis-à-vis the general public, especially entrepreneurs or insurance 
companies, because it can be erroneously used as a discriminating factor (Expert in 
preventive medicine and public health). In fact, this seems to confirm the findings of 
some of the studies mentioned above, which showed how insurance companies treated 
risk factors as if they were some sort of disease in their own right.  
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The access to genetic information also raised the issue of private patenting and 
benefits in relation to the socialisation of research costs, which was mentioned by 
Clarke’s study on biomedicalisation. One expert in particular expressed his/her concerns 
about using private genetic information, initially obtained for medical reasons, to 
develop tests, treatments or products later protected by a patent. In their opinion, this 
practice represents a form of unacceptable appropriation, which, apart from shifting 
benefits from the public good to private actors, does not even benefit those families 
providing the crucial genetic information. I quote:  
 
It is not acceptable that genetic information obtained without any cost from 
affected families turns into a source of commercial profit that impose to the 
people affected by the same disease enormous costs. When the genetic 
information is turned into a scientific successful research and an important 
gene is discovered, these results should be freely accessible by everyone. 
Unfortunately, it doesn’t work like this: the results of the research leads to the 
development of a specific diagnostic test for the discovered gene, which then 
gives raise to commercial exploitation (Genetist specialised in congenital 
anomalies).  
 
One of the hypotheses we derived from the literature review was that the diffusion 
of genetic medicine may be inducing the European health care systems to switch from 
preventive to predictive medicine, that is from the prevention of diseases to the genetic 
prediction of their future development. Although some agreed that medical research 
efforts are increasingly focusing on predictive medicine, the experts interviewed did not 
detect any significant shift in the ordinary medical practice. Yet, one of them pointed 
out how the uptake of some genetic testing into the ordinary healthcare system did not 
produce any beneficial outcomes, neither at the research nor at the therapeutical level.  
 
I believe that this shift is partially taking place. We are placing too much 
emphasis on the genetic causes of our common diseases, and too little on the 
measures that we should recommend once a genetic risk is identified. It may 
part of the normal process, but it is true that we did look for some studies 
focusing on the practices recommended to women diagnosed with BRCA1 to 
delay or avoid the insurgence of the disease and we found very little work 
done, generally of a very poor quality (Genetist specialised in congenital 
anomalies).  
 
The general picture coming out of the questions on participatory governance 
suggests that the experts would not support the idea of enlarging participation to the 
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extent of giving lay people decisional power, not because of the importance of 
technoscientific expertise, but because they acknoweldge the ultimate political nature of 
many of the issues related to the development and commercialisation of new genetic 
tests. The restricted access to the regulatory process was not justified on cognitive but 
on political grounds, because i) patient groups have a conflict of interests and ii) they 
are not democratically elected. Similar observations, though, were generally not raised 
against business companies, in a sense that they are often perceived as part of the game, 
as actors whose participation, given their propulsive role, is often taken for granted. 
In contrast, the majority of the experts suggested that patient groups should merely 
mediate between the scientific community, the medical personnel and the general public. 
Their practical expertise may be crucial to help the public to know the problem, to raise 
awareness and funds, to lobby for the recognition of the medical needs of their members 
and finally to draw the attention of researchers and healthcare administrators to specific 
health issues. However, one genetist suggested that patient groups may give a crucial 
contribution during the first stages of medical research, because their practical expertise 
on the daily management of given diseases.  
Although encouraging public participation at the consultative level, the experts 
closer to pure genetics tend to adopt a deficit model approach and to reduce the number 
of actors with decisional power participating to the decision making arena: 
I think that the health technicians and administrators, more than politicians, 
lawyers or bioethicists, should be actively involved in the governance 
mechanisms because they know well technical and budget issues. Otherwise 
there is a risk that the proposals approved in the parliament on the initiatives 
of lawyers and bioethicists, who know nothing of the reality of an hospital 
or of a laboratory, later will not find financial support.  
  
 Although acknowledging that the ultimate decision on biomedical research should 
always belong to elected bodies, one expert in bioethics placed great emphasis on the 
binding power of the opinions expressed by the Spanish multidisciplinary committees 
on assisted reproduction and on human tissues research:  
In the current legislature we are developing a system in which the opinions 
expressed by the specialised national spanish committees,  have a binding 
power on the political decision-makers, in the sense that if the committee 
opinion is favorable to the development of a research project, the political 
authority may still accept or reject, but if the opinion is negative the research 
project cannot be latter approved by the political authority.  
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Only the experts closer to an epidemiological approach approved of larger public 
participation at all levels, including the regulatory one. They insist that an 
overemphasis on genetic aspects of health is excessively individualizing medicine, 
neglecting the social and the environmental factors, which affects us all and which, 
therefore, should be considered and addressed by as many actors as possible.  
Finally, the expert on health technology assessment mentioned the recent 
implementation of a network of national committees on Public Health Genomics (PHG), 
as an attempt to constitute new participatory models of governance. The PhGen network, 
is expected to work as an ‘early detection unit’ for horizon scanning, fact finding, and 
monitoring of the integration of genome-based knowledge into public health 
(http://www.phgen.nrw.de/typo3/index.php). When studying its composition, one 
realizes that the PhGen network involves industry representatives but leaves out patient 
associations and consumer groups. Yet, it suggests the involvement of social scientists 
on the grounds that they bring in an expertise different from the one usually provided by 
lawyers or philosophers In the Spanish committee, there are two social scientists 
involved as such, but one has a philosophical background and the other a juridical one. 
The final question on patient choice and the possibility of sanctioning the citizens 
who conduct an unhealthy life-style, yielded substantially similar responses, which 
approve of a more active participation of patients in their health management, but 
clearly rejects the idea of discriminating them for their lifestyle. Yet, one expert in 
genetics suggests that a healthy lifestyle should be considered part of the therapy and 
therefore should be treated like an ordinary treatment. The expert in genetic anomalies 
pointed out that the idea of a patient choice is currently more an ideological fiction than 
a reality, given that serious educational programmes have not yet been implemented. 
The expert on health technology assessment suggested that the emphasis on patient 
choice may over emphasise individual responsibility, overlooking the social factors 
responsible for both the development of common diseases and the adoption of 
unhealthy lifestyles.   
In sum, both the economic indicators and the interviews seems to confirm some 
of the hypotheses formulated in the literature review. More specifically, Spain seems to 
be experiencing  a geneticization of research agenda, but not of the medical practice, 
with the notable exception of pre-natal and pre-implantation screening. Actually, the 
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fears about individual genetic discrimination resulting from adult pre-syntomatic 
genetic testing seems to be far from being empirically justified, although the 
geneticization of the research agenda may give rise to a social, indirect, form of genetic 
discrimination. The overwhelming investments on genetic research are reducing the 
efforts on other types of medical research and, possibly, also on the social welfare 
measures to support people already affected by both common and monogenetic diseases.  
The hypothesis suggesting that genetic information is not clinically but socially 
exceptional is also confirmed. The peculiarity of genetic data does not depend on its real 
predictive power, but on its permanent and shared nature and on the social perception 
and use by third parties. The hypothesis suggesting that pre-implantation and pre-natal 
genetic screening may endorse weak eugenics processes, i.e selective reproduction and 
abortion, is also fully confirmed. This phenomenon is also changing our conception of 
parenthood and reproduction, which now entails a sort of right to have ‘genetically 
healthy’ children. The overemphasis on genetic aspects of common diseases is 
reinforcing an individualistic approach to health, disease and healthcare, giving rise to a 
more consumerist approach to healthcare provisions, although this has not (yet) 
produced an over-responsabilization of the individual, which is the basis for 
discriminating healthcare policies.  
Finally, although generally reluctant to extend decisional power to civil society 
actors, the experts approve of general public participation and seem to be aware of the 
ultimate political nature of the governance system. Consequently, they know very well 
that the crucial issue is not the decision-making but the agenda setting processes, where 
they lobby and struggle exactly like any other social group. At this level, depending on 
their own agenda priorities, some experts want to include civil society organisations 
whilst others are ready to accept only the presence of industry representatives.  
 
4. Moving bioethics beyond ethics: a new role for the state? 
 
As we have seen, human genetics poses novel regulatory problems with regards to 
both research and healthcare issues to national policy makers, who are required to 
reconcile the conflicting political demands of civil society, science and industry. Given 
the complexity of the issues at stake and the variety of the actors potentially involved, 
the recent literature has predominantly focused on the formulation of new participatory 
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governance models and on democratisation of expertise. This literature took its start 
from the crisis of a policy making system based on the so called deficit model. 
According to the latter, the growing resistances shown by the general public to the 
development and the implementation of the new biotechnologies were essentially due to 
lack of adequate knowledge, scientific illiteracy and mistrust. Consequently, the first 
proposals to overcome what was essentially framed as a communicational impasse 
focused on improving scientific communication, reducing scientific illiteracy and 
building trust. This approach gave rise to a series of attempts to promote ‘educational 
participation’ (Bora 2004).  
Whilst successful in improving scientific literacy and awareness, these attempts in 
general failed to increase trust and encourage support. They also highlighted an 
educational paradox, which showed how higher education and above average scientific 
literacy were not necessarily associated to higher support or trust. Various studies, in 
fact, revealed that the resistance proceeding from the public was due more to social and 
cultural reasons than to scientific illiteracy, lack of knowledge and education or 
negative mass-media communications (Luján and Todt 2007).  
In the field of biomedicine and reproductive technology, the initial reaction to the 
failure of the deficit model encouraged the emergence of  a new discipline known as 
bioethics (Salter and Jones 2002). According to UNESCO, which was the first 
institution to set up a bioethical committee (IBC), bioethics is “a framework of thinking 
that relates to the principle that must guide human action in the face of the challenges 
raised by biology and genetics” (UNESCO 1997). Following the example of the 
UNESCO IBC, several national government set up national bioethics committees to 
address the ethical issues associated with genetic technologies and to enlarge 
participation to actors external to the techno-scientific circles. To ensure neutrality, 
multidisciplinarity and pluralism, these committees are meant to be composed of 
independent experts coming from a variety of disciplines.  
The bioethical debate focuses merely on the ethical implications of the new 
biotechnologies and aims at deriving legal guidelines from ‘scientific facts’ and abstract 
universal moral norms (Evans 2000; Bora 2005). Within the bioethical debate have so 
far emerged two main approaches. The first and most common approach focuses on the 
elaboration of universal bioethical guidelines, usually based on a common secular and 
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humanist framework (UNESCO, Universal Declaration on Bioethics, 2005). The second 
one, namely liberal eugenics, holds a laissez-faire approach and suggests reducing the 
political control over the development and the implementation of the new 
biotechnologies in order to let the market regulate the future directions of research and 
innovation progress (Buchanan et al. 2003; Agar 2004).  
After some ten years of workings, these committees have revealed a number of 
serious shortcomings. Whilst they proved only partially successful in enlarging 
participation (Bora 2004), their workings was often affected by serious impasses on 
some ethical issues, which bring in existential, non-negotiable beliefs. To overcome 
such impasses, mainstream bioethics has increasingly narrowed down the debate to very 
limited issues, related to privacy, individual consensus, right to objection or property 
rights diverting attention from the issues of politics and power, the political economy of 
genetic science (Evans 2002) and legitimizing specific conceptions of health, illness and 
healthcare, based on a peculiar understanding of individuality (Petersen 2006). 
Overlooking the constraints of socio-economic background,  the bioethical debate 
frames the individual as a universal, abstract consumer capable of making free informed 
choices about healthcare issues. In this way, the ethical gaze focuses exclusively on the 
needs and responsibilities of the individual, removing social issues and social dynamics 
from sight. The diffusion of genetic screening technologies is positively correlated with 
the growing consensus on the neoliberal patient-choice healthcare model, and favours a 
very consumerist approach to medicine and healthcare (Henderson and Petersen 2002), 
which reinforces genetic reductionism (McAfee 2003).  
Although it is certainly necessary to ascertain the ethically viability of new genetic 
technologies, ethics cannot constitute the ultimate basis for the decision making process 
(De Vries and Subedi 1998). When the ethical viability of a genetic technology is 
ascertained, its social desirability is automatically taken for granted without even trying 
to assess its social and political implications. Actually, the trends highlighted by the 
interviews and the general overview on the budget indicators seem to confirm the validity 
of the critiques advanced against both the technocratic and the bioethical models, which 
have been structurally unable to address the emerging social and political consequences, 
associated with the diffusion of genetic practices. Although the clinical practice has been 
so far almost unaffected, the research agenda seems to be increasingly being shaped by 
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genetics research up to an extent that seems to have no clinical justification so far. In turn, 
in spite of their overwhelming impact in the development of common diseases, 
environmental, social and cultural factors are increasingly being neglected by the research 
agenda. The predictive power of genetic screening techniques seems to have been largely 
overestimated, paving the way to a gradual diffusion of genetic tests that has not yielded 
significant clinical outcomes, has encouraged the genetisation of several common 
diseases and produced a massive recourse also in Spain to so called ‘weak eugenics’ 
practices, such as therapeutic abortion for selective reproduction.  
The complexity of these issues and the substantial disagreement among the experts 
on the real contribution of genetics, on the predictive power of genetic information and on 
the clinical validity of genetic testing for common diseases also provide serious 
arguments against even the technical feasibility of a regulatory decision-making process 
based merely on technocratic expertise. When dealing with governance issues, the experts 
have manifestly clustered around their own legitimate interests, defending freedom of 
research and often refusing the idea of extend decisional power to patient groups or civil 
society organisations. In other words, not only the experts are not able to reach a level of 
scientific consensus sufficient to constitute a reliable technical basis, but they are also far 
from being independent or objective about the main issues at stake. These findings cast 
some doubts about the overall contribution that technocratic expertise can provide. Whilst 
it may be useful and effective in addressing technical safety and quality of genetic testing 
(OECD Guidelines for Quality Assurance in Genetic Testing 2007), it seems to be far 
from being useful in terms of evaluating the prospect social – and often even the clinical –
benefits of genetic screening technologies. 
The outcomes of the interviews also show how the bioethical individualistic 
framework has become interiorised by the majority of the experts. The experts closer to a 
pure genetic approach framed the diffusion of genetic testing merely in terms of 
individual consensus, respect for individual autonomy, protection of individual and family 
privacy and defended it in the name of the ‘right to know’. In this respect, it is noteworthy 
that, although starting from different perspectives, both bioethicists and the genetists 
reached similar conclusions about the access to genetic testing and the model of 
governance to be adopted. This finding seems to confirm the idea that genetics and 
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bioethics mutually reinforce each other on the basis of a shared individualistic approach to 
respectively medical and ethical/legal problems.  
In 2005, Bora outlined the structural and cognitive limits of bioethical committees, 
constrained into the iron cage of a technoscientific normativity in which law contributes 
to scientific knowledge and science to normative knowledge, confining politics to a 
parasite role (Bora 2005). Very recently, A. Petersen argued: “The limitations of 
bioethics in addressing the unique challenges posed by genetics are becoming 
increasingly evident. In particular there is need to broaden the debate about the diverse 
implications of proposed and existing developments” (Petersen 2006: 495). In the light 
of the interviews, broadening the debate may actually constitute a first decisive step to 
widen the focus of the debates, to enlarge participation, to restore to sight the social and 
political issues overlooked by the narrow bioethical perspectives. In this respect, the 
inclusion of social and political scientists into current bioethical committees may help to 
include sociological expertise into the regulatory framework, whilst the inclusion of 
representative from civil society organizations may bring to the fore the concrete social 
needs of important sections of the society. 
The various attempts recently experimented in Denmark, UK and other countries, 
however, have shown a significant escalation of social conflicts among the various 
stake-holders (Bora 2007). Therefore, I wonder whether the problem would be more 
connected to the quality of the process rather than to the quantity of participation. In 
other words, the problem should be rephrased not so much in terms of how much 
participation is achieved but when and on what grounds is participation established.  
Very often the public is asked to intervene only at the regulatory stage, when the 
large majority of issues and topics have been already framed and settled. This procedure 
does not encourage participation and often fuels on frustrations, especially because of 
the very asymmetric cognitive and financial position of lay public compared to the 
companies.. The participation of CSOs and lay public should be more profitably and 
effectively included more upstream, at the agenda setting stage, when the society is still 
considering priorities and directions, interests and societal relevance of the various 
scientific innovation processes.  
The problems, however, do not only derives from the moment in which 
participation is invoked but also from the intellectual framework adopted so far.  
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According to Bora (2006, 2007), the crucial problem is due to the structural coupling of 
science and law in producing technoscientific norms. Bora argues that science and law 
have joined each other in a structural coupling and monopolised the debate, through the 
mechanism of double mis-reading. Mis-reading is the mechanism that allows structural 
coupling to work. In this case, external knowledge coming from societal actors 
belonging to societal systems other than science and law have been interpreted as a 
source of irritation leading the couple (science-law) to produce internal knowledge for 
decision-making. In turn, the synergy between science, officially providing expertise, 
and law, officially turning this expertise in normative decisions, has produced a 
technoscientific normative system that rigidly defines the legitimate objects of 
discussion, the specific definition of risk, carries the legitimate images of the “others” 
and of “society” congruent with the scientific view. Consequently, legal norms can only 
be criticised through legal rationality and scientific norms through scientific rationality. 
In other words, the structural coupling of science and law has rigidly structured the 
context and the rules of participatory science, ruling out non congruent knowledge, 
discourses and images belonging to other societal systems, especially to the social 
political realm. Outside these rigid structures and rules, participation simply is neither 
allowed nor considered legitimate. When a third party, who does not share a 
technoscientific normativity, comes to the fore, it is prevented from effective and 
profitable participation. In turn, frustration is generated and the escalation of conflict 
begins. Ultimately, exclusive dynamics are produced and the outcome (exclusion) is 
diametrically opposite to the intention (participation). 
In his conclusive remarks, Bora suggests that as long as the participatory 
governance models endorse a normative/legalistic framing, political discourses will be 
excluded. As a consequence, they might not be the appropriate setting for democratic 
political participation. He suggests to split the settings for governance in three systems, 
each of which is expected to rely on a specific societal form of knowledge, leaving to 
the political institutions (democratically elected and therefore accountable) the main 
tasks of mediation, coordination, synthesis and final decisions. The three settings should 
be a) Participatory Technology Assessments setting (science), b) local processes of 
consultation with general public for broad political participation (politics) and c) legal 
administrative procedures (law).  
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Building on Bora’s model, I suggests to separate the regulatory process in four 
consecutive steps. In the first step, the technical feasibily and safety of a given technology 
should be assessed. In the second step, the ethical viability should ascertained, although 
not only in relation to universal ethical norms but also in relation to the specific national 
cultural norms. In the third step, the social desirability should eventually be addressed. At 
this stage the contribution of economics, social and political science to identify and assess 
the economic, social and political implications of a large-scale diffusion of new medical 
technologies may provide crucial information to help the final proposal reach the fourth 
stage, identified by Bora in the local processes of consultation with general public for 
broad political participation. In this final step, all the main stakeholdsers should be 
involved, from patient associations and consumer groups to industry representatives, from 
local authorities to scientific communities.  
Yet, political participation comes at a cost. There can be no representation without 
taxation because sharing benefits imply also sharing duties. All the stakeholders 
participating should be asked, each in their own way, to help policy-makers to maximise 
the positive outcomes deriving from the introduction of a given technology and minimise 
the adverse social consequences. To give an example, if the generalisation of pre-natal 
genetic screening results in a reduction of public funds destined to social and medical 
support to people affected by the same disease for which the screening is introduced, the 
pharmaceutical industries may be asked to contribute to maintain the level of public funds 
constant over time, whilst patient associations may contribute intensifying their efforts 
toward the sensibilisation of the general public and to campaign for fund-raising.  
  If the principle of shared social responsibility becomes accepted, starting from the 
outcomes of the first three steps, the debate may truly restore the political discourse on 
social priorities, collective solidarity, bargaining and pluralism back to the center of the 
stage. On the one hand, the separation of technical committees in different procedural 
steps reduces the political power of technoscientific expertise without renouncing to its 
valuable contribution; and allows the ultimate decision to remain in the hands of the 
political body, granting to the State a new and central role. On the other hand, the 
progressive involvement of all the stakeholders, not merely on ethical or technical but 
also on social and political grounds, may help reconciling high participation with 
decisional efficacy.   
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Conclusion 
 
Drawing ispiration from some pioneer studies on biomedicalisation (A. Clarke 
2003) and geneticization (A. Petersen 2002, 2006), this paper has conducted a social 
and political analysis of the challenges that the diffusion of genetic screening practices 
increasingly poses to the current system of governance of biomedical innovation and 
healthcare policy. After having explored the extent to which the dynamics associated 
with biomedicalisation may actually be affecting the European social and political 
context, the paper has explored the most recent literature on the social and political 
implications associated with the diffusion of some genetic testing practices. Drawing 
from a series of indicators on research and health expenditure in Spain and on a series of 
semi-structured interviews to Spanish experts, the diffusion of some genetic testing 
technologies has been identified as a crucial component of the complex interaction 
between biomedicalisation and genetisation, which is actually fueling on the rapid 
increase of health expenditure while encouraging the geneticization of the research 
agenda and the emergence of new health care policies, based on an individualistic and 
consumeristic conception of health, disease and healthcare. Although we haven’t found 
any evidence of direct individual genetic discrimination associated with adult pre-
symptomatic testing, the possibility that a wrong social perception and use of genetic 
information may actually give rise to discrimination in insurance and working contexts 
cannot entirely be ruled out. In contrast, the diffusion of pre-natal and pre-implantation 
genetic testing is actually endorsing so called ‘weak eugenics’ processes, based on 
selective reproduction and medical abortion, which are, in turn, shifting the emphasis of 
publich health schemes from primary to secundary prevention.  
Although some novelties may come soon from very recent initiatives, such as the 
PHGEN (Public Health Genomics European Network), the paper comes to the 
conclusion that current systems of genetic technology regulation and policy – generally 
focusing on bioethical or technical consideration – are poorly participative and 
structurally unable  to address the social and political challenges posed by the actual and 
foreseen implications of the current genetic testing practices.  
To allow the state to actively and successfully respond to the above mentioned 
challenges, the paper suggests to broaden the dominant cognitive approach integrating 
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technical and ethical considerations with new insights from empirical studies on the 
social and political impact of a large-scale implementation of the new biomedical 
technologies. The paper also suggests to separate the assessment of the new 
technologies in four different steps (technical feasibility, ethical viability, social impact 
and desirability, political consensus) carried out by different bodies. In the fourth step, 
on the basis of the principle of shared social responsibility, the paper suggests to involve 
all the stakeholders not on ethical and technical but on social and political grounds.  
Reducing the political power of technical expertise without renouncing to its valuable 
contribution, and addressing explicitly social and political issues in health care decision 
making processes, these proposals may help reconciling high participation with 
decisional efficacy.  
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ANNEX I  
 
Questionnaire for semistructured interviews with experts in Spain 
 
 
1) Cuál es actualmente  la contribución de la genética en  
- ¿La investigación científica médica?   
- ¿La práctica clínica? 
- ¿El sistema sanitario en general?  
 
2) ¿Cuál será, en su opinión, la contribución de la genética a medio plazo, o sea en 
10-20 años? 
 
3) ¿Qué características tiene la información genética que la hacen diferenciarse de 
otros tipos de información médica  
- ¿Con respecto a su fiabilidad y capacidad de predecir? 
- ¿Con respecto a su confidencialidad y su acceso? 
 
4) ¿Qué factores, a parte de la información genética,  pueden tener influencia en la 
relación genotipo-fenotipo, especialmente con respecto al desarrollo de 
enfermedades? y ¿cómo valoraría la importancia de la correlación genotipo-
fenotipo? 
 
 
5) ¿Conoce usted algunos estudios, proyectos u otros tipos de investigación, en 
España o en Europa, que estudian la relación entre genotipos, fenotipos y otros 
tipos de factores en relación al desarrollo de enfermedades?  
 
6) En gran parte de la literatura reciente, sobre todo en el mundo anglosajón, se 
habla muy frecuentemente de la emergencia de un nuevo enfoque en la medicina, 
tanto en la investigación como en la práctica clínica, más enfocado sobre las 
causas genéticas de las enfermedades que en el tratamiento de sus consecuencias. 
¿Cree usted que exista este cambio y, en el caso de que exista, que opinión tiene 
sobre ésto?   
 
7) En los últimos años en España, así como en toda Europa, las pruebas genéticas 
de diagnostico y pre-sintomáticas, prenatal y para adultos, han tenido una gran 
difusión. Esta difusión ha sido defendida y apoyada por su capacidad de reducir 
la incidencia y el impacto de enfermedades debidas, al menos en parte a 
predisposiciones genéticas. ¿Cuál es su opinión? 
 
8) En las ultima décadas las asociaciones de enfermos se han interesado mucho en 
el desarrollo de las nuevas biotecnologías médicas. ¿En su opinión, cuál es – y 
cual debería ser –  el papel de las asociaciones de enfermos en  
- ¿La investigación científica médica?  
- ¿La práctica clínica? 
- ¿El sistema sanitario en general? 
- ¿La gestión y la regulación de las nuevas biotecnologías médicas? 
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9) En la literatura especializada sobre la regulación, la promoción y la gestión de 
las nuevas biotecnologías se propone cada día más frecuentemente el desarrollo 
y la adopción de nuevas formas de gobernanza, más participativa. ¿Está de 
acuerdo? ¿Qué enfoque deberían tener estas nuevas formas de gobernanza? 
¿Qué conocimiento e información debería tener quien pretende participar? ¿Y, 
en su opinión, quien debería participar? 
 
10) En Inglaterra se está desarrollando una nueva forma de política sanitaria, que 
atribuye mucha más responsabilidad sobre al paciente, con respecto a su 
conducta y a su estilo de vida, pero al mismo tiempo, le ofrece más posibilidades 
de elección en términos de acceso a la información, tipo de tratamiento, lugar y 
personal médico. ¿Cuál es su opinión sobre esto? ¿Cree que el Estado debería 
sancionar quien lleve un estilo de vida poco saludable?  
 
